SCHEMBL19711568

SCHEMBL19711568

Cc1ncc(I)c2c1CCNC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 4/20 0.38
HTR1D P28221 1/20 0.31
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
HTR1E P28566 1/20 0.31
HTR7 P34969 1/20 0.31
HTR2B P41595 1/20 0.31
HTR6 P50406 1/20 0.31
KDM4E B2RXH2 1/20 0.31
HTR5A P47898 1/20 0.31
NISCH Q9Y2I1 1/20 0.31
NR2E1 Q9Y466 1/20 0.31
SOS1 Q07889 1/20 0.30
CHRM3 P20309 1/20 0.30
TAAR1 Q96RJ0 1/20 0.30
RAD52 P43351 1/20 0.30
KMT2A Q03164 1/20 0.30
ADRA2A P08913 1/20 0.30
ADRA2B P18089 1/20 0.30
ADRA2C P18825 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19684580 0.81 PNMT (0.41) PNMTHTR7CHRM3ADRA2AADRA2B
SCHEMBL19678858 0.76 PNMT (0.36) PNMTHTR2AHTR2CHTR2B
SCHEMBL21986157 0.75 KDM4E (0.32) KDM4E
SCHEMBL19711559 0.70 HTR2C (0.39) PNMTHTR2CKDM4EHTR5ANISCH
SCHEMBL17348365 0.69 PNMT (0.37) PNMTHTR2CHTR6
SCHEMBL25678467 0.68 CYP1A2 (0.36) PNMTHTR2AHTR2CHTR2B
SCHEMBL12333209 0.68 HTR2A (0.35) PNMTHTR2AHTR2CHTR2BCHRM3
SCHEMBL19679229 0.67 CHRM2 (0.49) HTR2AHTR2CHTR2BHTR6CHRM3
SCHEMBL19711547 0.67 CHRNB2 (0.41) PNMTCHRM3ADRA2AADRA2BADRA2C
SCHEMBL23735162 0.67 PNMT (0.37) PNMTHTR2AHTR2CHTR6ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3464249-B1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER (US) 2021-08-11 EP disclosed
WO-2017213825-A1 TREATMENT METHODS HAVING REDUCED DRUG-RELATED TOXICITY AND METHODS OF IDENTIFYING THE LIKELIHOOD OF PATIENT HARM FROM PRESCRIBED MEDICATIONS TABULA RASA HEALTHCARE, INC. (US) 2017-12-14 WO disclosed